Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
$16.90
-6.5%
$14.17
$9.90
$20.76
$2.89B2.151.66 million shs2.16 million shs
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$8.17
-9.8%
$7.93
$5.37
$17.58
$591.19M1.791.32 million shs1.52 million shs
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
$34.71
-2.2%
$41.44
$14.78
$48.53
$2.16B0.29724,930 shs1.08 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$69.22
-6.4%
$57.14
$23.30
$80.50
$4.60B2.231.44 million shs2.47 million shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
-6.53%+11.55%+17.12%+13.80%+69.34%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-9.73%-12.91%-19.24%+25.04%+8.00%
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-2.20%-12.28%-15.75%+17.90%+55.72%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-6.37%+3.51%+16.28%+47.46%+127.40%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
$16.90
-6.5%
$14.17
$9.90
$20.76
$2.89B2.151.66 million shs2.16 million shs
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$8.17
-9.8%
$7.93
$5.37
$17.58
$591.19M1.791.32 million shs1.52 million shs
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
$34.71
-2.2%
$41.44
$14.78
$48.53
$2.16B0.29724,930 shs1.08 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$69.22
-6.4%
$57.14
$23.30
$80.50
$4.60B2.231.44 million shs2.47 million shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
-6.53%+11.55%+17.12%+13.80%+69.34%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-9.73%-12.91%-19.24%+25.04%+8.00%
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-2.20%-12.28%-15.75%+17.90%+55.72%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-6.37%+3.51%+16.28%+47.46%+127.40%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
2.63
Moderate Buy$19.5715.81% Upside
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
1.67
Reduce$8.504.10% Upside
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
2.83
Moderate Buy$61.8078.05% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.75
Moderate Buy$58.00-16.21% Downside

Current Analyst Ratings Breakdown

Latest DNA, TWST, ADPT, and ELVN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/2/2026
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
Boost Price TargetOutperform$45.00 ➝ $62.00
5/22/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Set Price Target$80.00
5/12/2026
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
Lower Price TargetEqual Weight$21.00 ➝ $18.00
5/12/2026
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
Initiated CoverageBuy$80.00
5/11/2026
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
UpgradeStrong-Buy
5/8/2026
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
Boost Price TargetBuy$41.00 ➝ $59.00
5/6/2026
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
Boost Price TargetBuy$19.00 ➝ $21.00
5/6/2026
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
Lower Price TargetOverweight$21.00 ➝ $19.00
5/6/2026
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
Reiterated RatingBuy$21.00
5/6/2026
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
Reiterated RatingBuy$22.00
5/5/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetBuy$55.00 ➝ $60.00
(Data available from 6/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
$276.98M9.76N/AN/A$1.47 per share11.50
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$170.15M3.13N/AN/A$8.74 per share0.93
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/AN/AN/AN/A$7.74 per shareN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$376.57M11.45N/AN/A$7.84 per share8.83
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
-$59.50M-$0.33N/AN/AN/A-16.82%-40.06%-16.64%8/4/2026 (Estimated)
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-$312.76M-$5.36N/AN/AN/A-215.41%-56.08%-26.06%8/6/2026 (Estimated)
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-$103.69M-$1.67N/AN/AN/AN/A-21.04%-20.41%8/12/2026 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$77.67M-$1.33N/AN/AN/A-19.85%-26.73%-19.15%8/3/2026 (Estimated)

Latest DNA, TWST, ADPT, and ELVN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-$0.44-$0.38+$0.06-$0.38N/AN/A
5/5/2026Q1 2026
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
-$0.16-$0.13+$0.03-$0.13$61.03 million$70.87 million
5/4/2026Q2 2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.49-$0.71-$0.22-$0.71$107.64 million$110.72 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
N/AN/AN/AN/AN/A
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
N/AN/AN/AN/AN/A
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
N/A
3.35
3.22
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
N/A
5.15
5.15
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/A
40.32
40.32
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
2.70
2.42

Institutional Ownership

CompanyInstitutional Ownership
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
99.17%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
78.63%
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
95.08%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A

Insider Ownership

CompanyInsider Ownership
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
5.70%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
12.69%
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
3.00%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.08%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
790160.04 million150.92 millionOptionable
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
64065.32 million57.03 millionOptionable
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
5060.90 million59.08 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99062.27 million60.35 millionOptionable

Recent News About These Companies

Twist Bioscience (TWST) Gets a Buy from Guggenheim

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adaptive Biotechnologies stock logo

Adaptive Biotechnologies NASDAQ:ADPT

$16.90 -1.18 (-6.53%)
Closing price 06/5/2026 04:00 PM Eastern
Extended Trading
$17.40 +0.50 (+2.93%)
As of 06/5/2026 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Ginkgo Bioworks stock logo

Ginkgo Bioworks NYSE:DNA

$8.16 -0.89 (-9.78%)
Closing price 06/5/2026 03:59 PM Eastern
Extended Trading
$8.14 -0.03 (-0.37%)
As of 06/5/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Enliven Therapeutics stock logo

Enliven Therapeutics NASDAQ:ELVN

$34.71 -0.78 (-2.20%)
Closing price 06/5/2026 04:00 PM Eastern
Extended Trading
$34.74 +0.03 (+0.10%)
As of 06/5/2026 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$69.22 -4.71 (-6.37%)
Closing price 06/5/2026 04:00 PM Eastern
Extended Trading
$70.68 +1.46 (+2.11%)
As of 06/5/2026 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.